DS
VIR icon

David Shaw’s Vir Biotechnology VIR Stock Holding History

David Shaw’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.24M Sell
416,403
-401,282
-49% -$3.82M ﹤0.01% 2536
2026
Q1 		$7.33M Buy
817,685
+767,893
+1,542% +$6.12M ﹤0.01% 1876
2025
Q4 		$300K Buy
49,792
+16,268
+49% +$96.9K ﹤0.01% 4151
2025
Q3 		$191K Sell
33,524
-2,733
-8% -$14K ﹤0.01% 4293
2025
Q2 		$183K Sell
36,257
-470,447
-93% -$2.52M ﹤0.01% 4067
2025
Q1 		$3.28M Buy
506,704
+4,704
+0.9% +$41.8K ﹤0.01% 2217
2024
Q4 		$3.68M Sell
502,000
-428,655
-46% -$3.38M ﹤0.01% 2235
2024
Q3 		$6.97M Buy
930,655
+8,101
+0.9% +$70.4K 0.01% 1680
2024
Q2 		$8.21M Buy
922,554
+276,300
+43% +$2.65M 0.01% 1464
2024
Q1 		$6.55M Sell
646,254
-122,890
-16% -$1.25M 0.01% 1681
2023
Q4 		$7.74M Sell
769,144
-111,087
-13% -$1.02M 0.01% 1572
2023
Q3 		$8.25M Buy
880,231
+826,696
+1,544% +$11.8M 0.01% 1421
2023
Q2 		$1.31M Sell
53,535
-13,765
-20% -$346K ﹤0.01% 2922
2023
Q1 		$1.57M Buy
67,300
+22,305
+50% +$570K ﹤0.01% 2860
2022
Q4 		$1.14M Buy
44,995
+30,177
+204% +$740K ﹤0.01% 3353
2022
Q3 		$286K Buy
14,818
+6,230
+73% +$158K ﹤0.01% 4321
2022
Q2 		$219K Sell
8,588
-43,642
-84% -$1.02M ﹤0.01% 4510
2022
Q1 		$1.34M Sell
52,230
-92,572
-64% -$2.75M ﹤0.01% 3665
2021
Q4 		$6.06M Sell
144,802
-22,324
-13% -$875K 0.01% 2175
2021
Q3 		$7.27M Sell
167,126
-52,102
-24% -$2.26M 0.01% 1777
2021
Q2 		$10.4M Buy
219,228
+102,936
+89% +$4.68M 0.01% 1466
2021
Q1 		$5.96M Buy
116,292
+94,721
+439% +$5.1M 0.01% 1721
2020
Q4 		$578K Buy
+21,571
New +$701K ﹤0.01% 3321

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

David Shaw's VIR Position: Q2 2026 in Review

David Shaw reduced its Vir Biotechnology (VIR) stake by 49% in Q2 2026, selling an estimated $3.82M and leaving 416,403 shares worth $4.24M. The position accounts for ﹤0.01% of the portfolio, ranked #2536.

David Shaw first reported a position in VIR in Q4 2020 and has held it in 23 quarters since. The position peaked at $10.4M in Q2 2021. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • David Shaw held 416,403 shares of Vir Biotechnology worth $4.24M as of Q2 2026.
  • David Shaw sold 401,282 Vir Biotechnology shares in Q2 2026, an estimated $3.82M.
  • Vir Biotechnology made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2536 holding.
  • David Shaw first reported a position in Vir Biotechnology in Q4 2020 and has held it in 23 quarters since.
  • David Shaw's Vir Biotechnology position peaked at $10.4M in Q2 2021.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.